AOI Biosciences

AOI Biosciences is a Japanese biotechnology company founded in 2019 and headquartered in Ibaraki, Osaka, with an additional office at Osaka University. The company develops diagnostic and therapeutic solutions for autoimmune and immune-related diseases based on its proprietary Neo-Self theory, a novel mechanistic framework for understanding autoimmune conditions. Its core diagnostic offering is the β2GPI Neo-Self antibody test for infertility and recurrent pregnancy loss. AOI Biosciences also applies advanced bioinformatics and quantum-inspired optimization (in collaboration with Toshiba's SQBM+ platform) to support drug discovery and biomarker development for pharmaceutical partners.